knowledge -WSS

knowledge

author：focus 2025-09-14 10:05:28 - browse：98286

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Readout Newsletter: The latest on Moderna, Apellis, and Merck

WSS

What don’t we know about an Alzheimer’s drug side effect?

The EPA's new lead rule: How one expert crunched the numbers

SNAP should offer more nutrition education

Editas, Vertex strike deal on CRISPR

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Mayo Clinic plans $5B tech

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

What don’t we know about an Alzheimer’s drug side effect?

What does generative AI mean for health care? We asked experts

How to pay for weight loss drugs and save Medicare

Anesthesiologist group: stop taking Ozempic before surgery

With clinical trial data readouts, here's how to spot spin

FDA approval of Sarepta Duchenne genetic therapy gives me hope

HCA sued by state AG for quality issues at Mission Health

Guidelines to prevent youth baseball injuries need more muscle

David Ricks of Eli Lilly: best biopharma CEO of 2023

focus

CDC director unscathed in first congressional testimony

How to keep neuroscience’s past racism from being its future

David Ricks of Eli Lilly: best biopharma CEO of 2023

How to keep neuroscience’s past racism from being its future

Christmas in the PICU brings some surprising joy

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

focus

Wikipedia

explore

leisure time